ClinicalTrials.gg
CompletedNCT07775989Updated Nov 6, 2026

Evaluation of the Efficacy and Safety of Dallixa® Eyebrow Serum (Produced by Quantum Aesthetics Cosmetics, Turkey) in Subjects With Eyebrow Hypotrichosis

An interventional study of dermo cosmetic product in Hypotrichosis, sponsored by Quantum Aesthetics Cosmetics. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Quantum Aesthetics Cosmetics · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Aug 2025, registered Aug 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A retrospective, single arm, and interventional Clinical Trial

02

Conditions studied

  • Hypotrichosis

Browse trials for

03

In context

Hypotrichosis

24 studies on the registry are indexed under Hypotrichosis; 2 are open to participants now.

This study's enrollment of 49 is below the median of 56 across 22 interventional studies indexed under Hypotrichosis.

Browse Hypotrichosis studies →

Lead sponsor

Quantum Aesthetics Cosmetics is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals of any sex and at least 18 years of age
  2. Subjects who have inadequate eyebrow due to natural causes (eyebrow hypotrichosis)
  3. A Grade 1 or 2 on the Global Eyebrow Assessment (GEBA) scale
  4. Subjects who agree to forgo any additional treatment to the brows, such as waxing, plucking, threading and/or tinting, laser hair removal, and/or bleaching for the duration of the study.
  5. Willing to complete all required study visits, procedures, and evaluations including photography.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any uncontrolled systemic disease (like systemic diseases which could prevent hair growth or produce abnormal growth)
  2. known diagnoses possibly underlying or contributing to the state of the eyebrows including, but not limited to, telogen effluvium or anagen effluvium
  3. Any known diseases, infection or abnormalities to the eyelid or eyebrow (including eczema, seborrheic dermatitis, alopecia areata, trichotillomania, thyroid diseases, atopic dermatitis, history of trauma or burn to the eyebrow region and etc.)
  4. Subjects that have thinning brows as a result of over plucking, trichotillomania, chemotherapy or any other condition or treatment that causes hair loss.
  5. Patients with permanent eyebrow loss due to over-grooming
  6. Allergy to any component of the product
  7. Subjects with temporary or semipermanent eyebrow fillers, any permanent or semi-permanent tint, dye or bleaching within 3 months
  8. Any skin pigmentation/depigmentation, microblading, tattoos, permanent eye and/or eyebrow make-up, moles, scars, or other characteristics within the eyebrow area
  9. Subjects who used permanent injectable fillers in and around the eyebrow area within 12 months
  10. Use of any over-the-counter or prescription eyebrow growth product within 3 months
  11. Subjects who had undergone any facial surgery (e.g., brow lift) or eyebrow extension within 3 months of screening
  12. Current enrollment in an investigational product or device or participation in such a study within 30 days
  13. Aphakic subjects and/or pseudophakic subjects with a torn posterior lens capsule
  14. Subjects with known risk factors for macular edema
  15. Patients with a history of glaucoma and/or increased ocular pressure
  16. Patients who are currently using an IOP-lowering prostaglandin analog
  17. Previous cosmetic surgery to the upper face (e.g., periorbital surgery, brow lift, eyelid or eyebrow surgery, etc.).
  18. Any planned facial cosmetic procedure that would interfere with the evaluation of the eyebrows
  19. Participation in another investigational product or device study within the last 30 days
  20. Females who are pregnant, nursing, or planning a pregnancy during the study, or who are of and not using a reliable method of
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Dallixa® Eyebrow Serum

    Other: dermo cosmetic product

Interventions

  • Otherdermo cosmetic product

    dermo cosmetic product like herbal or vitamin ingredients

06

What researchers measure

Primary outcomes

  1. The proportion of subjects with ≥ 1-grade increase in GEBA Score at month 5

    Time frame: at 5 month

Secondary outcomes

  1. The proportion of subjects with ≥ 1-grade increase in the GEBA at month 2

    Time frame: at month2

  2. Change from baseline in eyebrow diameter at month 2 and 5 (Based on DIA)

    Time frame: at month 2 and 5

  3. Change from baseline in eyebrow density at month 2 and 5 (Based on DIA)

    Time frame: at month 2 and 5

  4. The proportion of satisfied subjects (very satisfied/mostly satisfied) on Eyebrow Satisfaction Scale (ESS) Item 6 at month 2 and 5

    Time frame: at month 2 and 5

  5. Adverse events reported from the baseline and during the study period (from the baseline up to week 20)

    Time frame: from the baseline up to week 20

07

Study locations

1 site
  • Akdeniz Üniversitesi Hastanesi
    Antalya, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — no planing to share individual participant data yet

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Apr 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Aug 20, 2026
StartActual
Aug 28, 2025
Primary completionActual
Apr 20, 2026
CompletionActual
Apr 20, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and description
1 update, last Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Minor edits only
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07775989
Lead sponsor
Quantum Aesthetics Cosmetics
Responsible party
Sponsor
First posted
Aug 20, 2026
Start date
Aug 28, 2025
Primary completion
Apr 20, 2026
Completion
Apr 20, 2026
Last update
Nov 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion